Welcome to our dedicated page for ZEO ScientifiX news (Ticker: zeox), a resource for investors and traders seeking the latest updates and insights on ZEO ScientifiX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZEO ScientifiX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZEO ScientifiX's position in the market.
ZEO ScientifiX (OTCQB:ZEOX) announced it has trained more than 500 physicians through its one-day monthly Masterclass series, averaging 70+ clinicians per month. The program covers Florida regulatory requirements, evidence-based science, ethical sourcing, manufacturing quality, and operational practice integration.
The Masterclass features legal, Ph.D., and clinical experts, includes a tour of ZEO ScientifiX research facilities, and the next session is scheduled for April 24, 2026 at Nova Southeastern University's Center of Innovation.
ZEO ScientifiX (OTCQB:ZEOX) entered an exclusive memorandum of understanding with Regen Therapy on April 9, 2026, to serve as Regen's core supplier for advanced biologic therapeutics, while Regen partners with Stealth Health to deploy white‑label telemedicine and longevity services across >3,000 clinics and 24,000 practitioners.
The integrated model combines ZEO biologics, Stealth Health prescriber/pharmacy infrastructure, and Metabolic Code® analytics to deliver scalable, clinic‑embedded regenerative and longevity care through cGMP processes.
ZEO ScientifiX (OTCQB: ZEOX) was selected as a Qualified Team advancing to the XPRIZE Healthspan Semi-Finals on April 7, 2026, a $101 million competition targeting restoration of muscle, cognitive, and immune function by at least 10 years in people aged 65–80 within one year.
ZEO will prepare a Finals Application and pursue controlled clinical evaluation of its extracellular vesicle (exosome) therapeutics and delivery systems, leveraging its Nova Southeastern University research facilities and a multidisciplinary team of regenerative-medicine experts.
Zeo ScientifiX (NASDAQ:ZEOX), Cytora Therapeutics, and Made Scientific announced a three-way U.S. partnership on Jan 7, 2026 to manufacture and commercialize Cytora's allogeneic oral mucosal stem cell therapy.
The collaboration names Made Scientific as exclusive U.S. GMP manufacturer (Princeton, NJ) and Zeo as exclusive U.S. commercial partner, while Cytora continues clinical and regulatory development and grants manufacturing rights. Initial commercialization will pursue Florida's SB 1768 pathway and parallel U.S. FDA Phase 2b IND activity toward an approved FDA license.
Key figures: lead indication diabetic foot ulcers with ~125,000 new Florida patients annually and a target category of >3.6 million annual cases in-state. Cytora's hOMSC200 Phase 1/2a showed a favorable safety profile and statistically significant wound-area reduction with complete closures in chronic ulcers (average duration 27 months).
ZEO ScientifiX (OTCQB:ZEOX) says Florida's new stem cell law, SB 1768 (effective July 1, 2025), creates pathways to market non‑FDA‑approved human tissue‑derived therapies under cGMP and informed consent rules.
The company expects increased demand, medical tourism return, and faster clinical progress in Florida. ZEO recently launched an IRB‑approved open‑label trial of PPX to enroll up to 350 patients; 5 clinics are participating and 7 patients are enrolled to date. ZEO is evaluating lab expansion at Nova Southeastern University to add clean rooms and research space to support product and trial capacity.
ZEO ScientifiX (OTCQB:ZEOX) is positioning itself for growth following Florida's new SB-1768 stem cell law, which authorizes the use of non-FDA-approved stem cell therapies for certain conditions. The company has launched strategic initiatives including:
The company's platform includes ethically sourced biologics developed in an FDA-registered, cGMP-compliant facility. To support its expansion, ZEO has launched a new website and partnered with Plus4 Public Relations and Small Circle creative agency to strengthen its market presence.
Under interim CEO Ian Bothwell's leadership, ZEO aims to establish industry standards through its product platform, partnerships, and physician education initiatives as Florida opens its regenerative medicine market.
ZEO ScientifiX (OTCQB:ZEOX) has announced the launch of ZEO Masterclass, a physician-focused educational initiative ahead of Florida's SB-1768 law implementation on July 1, 2025. The new law will allow licensed MDs and DOs to offer non-FDA-approved stem cell therapies for specific medical indications under strict compliance protocols.
The four-hour intensive training will be held on June 27th at NOVA Southeastern University, covering legal compliance, clinical integration, and scientific insights for stem cell and exosome therapies. The program aims to prepare physicians for implementing regenerative therapies in areas including pain management, wound healing, and orthopedics.
ZEO ScientifiX (OTCQB:ZEOX) has appointed Dr. Peter A. M. Everts as Chief Scientific and Technology Officer. Dr. Everts brings over 35 years of experience as a clinician, researcher, and executive, specializing in medical devices and biological therapies.
Prior to joining ZEO, he served as Chief Scientific Officer at EmCyte and Educational Program Director at Gulf Coast Biologics. He co-founded the Da Vinci Clinic in the Netherlands in 2010 and held senior leadership roles at Avance Medical. Dr. Everts earned his Ph.D. from the University of Utrecht and holds professorships at the University of Queensland and Max Planck University.
The appointment aims to accelerate innovation in biological therapeutics for regenerative medicine and advance the company's clinical trial portfolio. Ian Bothwell, Interim CEO and CFO, emphasized that this strategic addition reinforces ZEO's market position in the biologic medicine industry.
ZEO ScientifiX (OTCQB:ZEOX) has provided a comprehensive business update highlighting several key achievements and future plans. The company successfully completed Phase I clinical trials for its flagship product Zofin™ and is now positioned to pursue Phase II trials targeting multiple indications.
Notable developments include significant growth in sales of their PPX™ product, with revenue increasing by approximately $474,000 for the fiscal year ended October 31, 2024. The company established strategic partnerships with healthcare providers, including Physicians Group, , which operates 75 clinics.
In December 2024, ZEO launched ZEO HAIR GROW™ in collaboration with Exotropin , targeting the hair loss market. The company operates a cGMP FDA compliant research facility and has secured patents for their amniotic fluid product and PPX™ technology. Looking ahead to 2025, ZEO aims to advance clinical trials and is in negotiations for funding to commence Phase II trials as early as Q2 2025.
ZEO ScientifiX (OTCQB:ZEOX) has partnered with affiliate Exotropin to launch ZEO HAIR GROW™, a hair growth solution targeting the 66 million Americans affected by hair loss. The system combines extracellular vesicles from amniotic fluid, adipose stromal cells, and aloe vera plant to optimize scalp health. The product consists of three components: ZEO GROW X™ and ZEO GROW BOOST™ for in-office use, and EXO FOLLICLE FUEL™ for at-home application. The solution will be introduced at the Medical Aesthetics Professionals meeting in Scottsdale, Arizona, November 14-16, 2024.